The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

被引：94
|
作者：
Kaiser-Guignard, Julie [1 ]
Canellini, Giorgia [2 ]
Lion, Niels [2 ]
Abonnenc, Melanie [2 ]
Osselaer, Jean-Claude [2 ]
Tissot, Jean-Daniel [2 ]
机构：
[1] CHU Vaudois, Serv Hematol, CH-1011 Lausanne, Switzerland
[2] Serv Reg Vaudois Transfus, CH-1066 Epalinges, Switzerland
来源：
BLOOD REVIEWS | 2014年 / 28卷 / 06期
关键词：
Amotosalen; Hemovigilance; Pathogen inactivation; Pathogen reduction; Platelets; Platelet concentrates; Riboflavin; Transfusion; IN-VITRO EVALUATION; INTERSTRAND CROSS-LINKS; INTERCEPT BLOOD SYSTEM; THERAPEUTIC-EFFICACY; FUNCTIONAL-CHARACTERISTICS; PHOTOCHEMICAL TREATMENT; AMOTOSALEN-HCL; BLEEDING COMPLICATIONS; PROTEIN-SYNTHESIS; ADDITIVE SOLUTION;
D O I：
10.1016/j.blre.2014.07.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity. (C) 2014 The Authors. Published by Elsevier Ltd.
引用
收藏
页码：235 / 241
页数：7
相关论文
共 50 条
  • [1] Pathogen inactivation of platelet concentrates
    Reesink, H. W.
    Panzer, S.
    McQuilten, Z. K.
    Wood, E. M.
    Marks, C.
    Wendel, S.
    Trigo, F.
    Biagini, S.
    Olyntho, S.
    Devine, D. V.
    Mumford, I.
    Cazenave, J. -P.
    Rasongles, P.
    Garraud, O.
    Richard, P.
    Schooneman, F.
    Vezon, G.
    Al Radwan, R.
    Brand, A.
    Hervig, T.
    Castro, E.
    Lozano, M.
    Navarro, L.
    Puig, L.
    Almazan, C.
    MacLennan, S.
    Cardigan, R.
    Franklin, I. M.
    Prowse, C.
    VOX SANGUINIS, 2010, 99 (01) : 85 - 95
  • [2] Pathogen inactivation in platelet concentrates: The French experience
    Cazenave, J. -P.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2011, 18 (04) : 478 - 484
  • [3] Model Calculations to Quantify Clinical and Economic Effects of Pathogen Inactivation in Platelet Concentrates
    Berger, Karin
    Bauer, Matthaeus
    Schopohl, Dorothee
    Henschler, Reinhard
    Ostermann, Helmut
    ONKOLOGIE, 2013, 36 (1-2): : 53 - 59
  • [4] Analysis of reasons for not implementing pathogen inactivation for platelet concentrates
    Lozano, M.
    Cid, J.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2013, 20 (02) : 158 - 164
  • [5] Economics of Pathogen Inactivation Technology for Platelet Concentrates in Japan
    Ulf Staginnus
    Laurence Corash
    International Journal of Hematology, 2004, 80 : 317 - 324
  • [6] Pathogen inactivation of platelet concentrates and fresh frozen plasma
    Jackson, JE
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2003, 60 (04) : 227 - 232
  • [7] Economics of pathogen inactivation technology for platelet concentrates in Japan
    Staginnus, U
    Corash, L
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (04) : 317 - 324
  • [8] Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland
    Jutzi, Markus
    Taleghani, Behrouz Mansouri
    Rueesch, Morven
    Amsler, Lorenz
    Buser, Andreas
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2018, 45 (03) : 151 - 156
  • [9] Bacterial contamination of platelet concentrates: pathogen detection and inactivation methods
    Vedy, Dana
    Robert, Daniel
    Gasparini, Danielle
    Canellini, Giorgia
    Waldvogel, Sophie
    Tissot, Jean-Daniel
    HEMATOLOGY REPORTS, 2009, 1 (01) : 22 - 28
  • [10] Pathogen inactivation/reduction of platelet concentrates: turning theory into practice
    Gathof, B. S.
    Tauszig, M. E.
    Picker, S. M.
    STATE OF THE ART PRESENTATIONS, 2010, 5 (01): : 114 - 119
12345